StockTitan

@stocktitan.net

2 weeks ago

Aclarion installs 1-year takeover defense, keeps door open to fair bids Effective immediately, the plan runs for one year and gives the board more time to weigh control bids and seek an appropriate premium for stockholders.

#ACON #ACONW Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

www.stocktitan.net/news/ACON/aclarion-inc-a...

StockTitan

@stocktitan.net

2 weeks ago

Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts Aclarion (Nasdaq: ACON, ACONW) published a CEO shareholder letter outlining 2026 priorities: expand adoption of the Nociscan platform, pursue reimbursement with U.S. regional insurers, grow clinical evidence, and advance commercial engagement with physicians and imaging centers.The company highlighted an initial CLARITY trial readout in Q4 2026 and a strong balance sheet with cash runway into 2028 to support execution of these catalysts.

#ACON #ACONW Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

www.stocktitan.net/news/ACON/aclarion-publi...

StockTitan

@stocktitan.net

2 months ago

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)

#ACON #ACONW Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

www.stocktitan.net/news/ACON/aclarion-stren...

StockTitan

@stocktitan.net

2 months ago

Aclarion Provides 2025 Update and 2026 Corporate Outlook Aclarion (Nasdaq: ACON / ACONW) provided a 2026 corporate outlook and 2025 operational update centered on its Nociscan platform for chronic low back pain. Key metrics: 2025 annual scan volumes +69% YoY, Q4 2025 volumes +114% YoY. The company reported a debt-free balance sheet with $12.0 million cash as of Dec 31, 2025, following >$22.0 million equity raised in 2025, and expects cash to fund operations into H1 2027. Clinical progress includes the CLARITY trial (7 activated sites) with a goal to enroll ~25% of patients by end of Q2 2026 and an initial internal 3-month readout anticipated in Q3 2026. Additional 2025 milestones: 9 new imaging centers, 22 new physician users, and 4 issued patents.

#ACON #ACONW Aclarion Provides 2025 Update and 2026 Corporate Outlook

www.stocktitan.net/news/ACON/aclarion-provi...

StockTitan

@stocktitan.net

2 months ago

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data Aclarion (Nasdaq: ACON) announced first patient enrollments at two additional CLARITY trial sites (Northwestern Medicine and Scripps Health), bringing the number of sites that completed regulatory setup to seven and sites that have enrolled patients to four.The multi-site pivotal CLARITY trial will randomize up to 300 patients to evaluate Nociscan-guided surgical planning versus blinded care. The company expects an initial interim readout after the first cohort reaches a 3-month follow-up, projected in 3Q 2026, and aims to enroll ~25% of patients by end of Q2 2026. Full enrollment target is mid-2027, with possible early termination if significance is reached earlier.

#ACON #ACONW Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

3 months ago

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) Aclarion (Nasdaq: ACON) announced publication of a featured Tech Update on its Nociscan solution in the Special Pain Issue of the International Journal of Spine Surgery (IJSS) on Dec 4, 2025. The article highlights a clinical case where a 27-year-old with chronic low back pain had MRI-suspected L4/5 and L5/S1 pathology; a four-level Nociscan exam detected biomarkers at L5/S1 only, guiding the surgeon to perform a single-level artificial disc replacement at L5/S1 that eliminated the patient’s pain and restored activity. The release emphasizes Nociscan as a noninvasive, evidence-supported SaaS platform for distinguishing painful versus nonpainful lumbar discs and notes IJSS’s role in disseminating spine care innovations to an international audience.

#ACON #ACONW Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

5 months ago

Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets

#ACON #ACONW Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst

www.stocktitan.net/news/ACON/aclarion-provi...

StockTitan

@stocktitan.net

5 months ago

Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference Aclarion (Nasdaq: ACON) participated in the International Society of Pain and Neuroscience Annual Meeting in London on Oct 13, 2025, where a session co‑moderated by Doug Beall, M.D., highlighted the role of MR Spectroscopy and Aclarion’s Nociscan in identifying biomarkers of discogenic low back pain.Nociscan is described as a SaaS platform that converts MR spectroscopy signals into objective biomarkers to help differentiate painful vs non‑painful lumbar discs and inform personalized treatment decisions. The company emphasized multidisciplinary clinical engagement and insurer approval at a UK clinic for study access.

#ACON #ACONW Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

6 months ago

Revolutionary AI Platform Shows 54% Success Rate Improvement Potential in Chronic Back Pain Treatment Aclarion's Nociscan combines MR spectroscopy with AI to identify painful lumbar discs. 300-patient CLARITY trial ongoing, targeting improvement beyond 54% industry success rate. Results expected Q2 2026.

#ACON #ACONW Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers

www.stocktitan.net/news/ACON/aclarion-prese...

StockTitan

@stocktitan.net

6 months ago

First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial Aclarion (NASDAQ:ACON) has announced the enrollment of its first two patients at UHealth – University of Miami Health System in the pivotal CLARITY trial for its Nociscan technology. The study will evaluate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain patients.The CLARITY trial will enroll 300 patients across multiple US sites, with patients randomized in a 1:1 ratio between surgeons blinded and unblinded to Nociscan results. The trial's primary endpoint is measuring change in back pain at 12 months post-surgery, with interim results expected in Q2 2026.Nociscan is the first evidence-supported SaaS platform that helps physicians identify painful discs in the lumbar spine through MR Spectroscopy and AI technology, addressing a condition affecting approximately 266 million people globally.

#ACON #ACONW First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial

www.stocktitan.net/news/ACON/first-patients...

StockTitan

@stocktitan.net

7 months ago

Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts Aclarion (NASDAQ:ACON) reported significant growth in its Nociscan scan volumes, with a 132% year-over-year increase from Q2 2024 to Q2 2025. The company achieved two consecutive quarters of scan volume growth for the first time, driven by new physician adoption and UK insurance coverage.Key developments include: the enrollment of the first patient in the pivotal CLARITY trial, which aims to validate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain; publication of a cost-effectiveness analysis showing Nociscan is more effective and less costly than provocative discography; and approval from three major UK private insurers, providing access to over 5.2 million people.The company reaffirmed its cash runway through Q3 2026, with approximately $15M net cash on hand and no debt. Aclarion expects continued quarter-over-quarter growth throughout 2025 and anticipates internal interim CLARITY trial results by Q2 2026.

#ACON #ACONW Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

www.stocktitan.net/news/ACON/aclarion-provi...

StockTitan

@stocktitan.net

8 months ago

Healthcare Tech Company Aclarion Extends Stockholder Voting Period - Critical Meeting Updates Key voting deadline July 20 for Aclarion's rescheduled Annual Meeting. Healthcare AI firm seeks additional stockholder participation. Check voting instructions.

#ACON #ACONW Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

www.stocktitan.net/news/ACON/aclarion-inc-a...

StockTitan

@stocktitan.net

9 months ago

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial Aclarion (NASDAQ:ACON) has announced the enrollment of its first patient in the CLARITY trial at the Texas Back Institute. The trial aims to evaluate Nociscan's clinical and economic value in spine surgery. Nociscan is a SaaS platform that helps physicians identify sources of chronic low back pain using MR Spectroscopy and AI technology.The CLARITY trial will enroll 300 patients across multiple US sites, studying 1- or 2-level discogenic low back pain surgical treatments. The randomized study will compare outcomes between surgeons with and without access to Nociscan data. The company expects interim results in Q2 2026, with the primary endpoint measuring changes in back pain at 12 months post-surgery.

#ACON #ACONW First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

www.stocktitan.net/news/ACON/first-patient-...

StockTitan

@stocktitan.net

9 months ago

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site Aclarion (NASDAQ: ACON) has announced the addition of UHealth - University of Miami Health System and Miller School of Medicine as a site for their CLARITY clinical trial. The trial aims to evaluate Nociscan, a technology that uses MR Spectroscopy and AI to identify sources of chronic low back pain. CLARITY is a prospective, randomized study that will enroll 300 patients across multiple US sites, including Johns Hopkins Medicine and Northwestern Medicine. The study will assess Nociscan's effectiveness in guiding surgical treatments for discogenic low back pain, with patients randomized between surgeons who are blinded and unblinded to Nociscan results. Dr. Gregory Basil, Director of Endoscopic Spine Surgery at UHealth, emphasized the importance of personalized treatment approaches and novel technologies in spine surgery. The trial's primary endpoint is measuring change in back pain at 12 months post-surgery compared to baseline.

#ACON #ACONW Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

www.stocktitan.net/news/ACON/aclarion-adds-...

StockTitan

@stocktitan.net

10 months ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site Aclarion (NASDAQ: ACON) has announced the addition of Keck Medical Center of USC as a site for its CLARITY clinical trial. The trial aims to evaluate Nociscan, Aclarion's technology that uses biomarkers and AI algorithms to identify sources of chronic low back pain. The CLARITY study will enroll 300 patients across multiple US centers, including Johns Hopkins Medicine, Northwestern Medicine, Advocate Aurora Research Institute, and Texas Back Institute.The randomized trial will assess patients scheduled for 1- or 2-level discogenic low back pain surgery, with surgeons either blinded or unblinded to Nociscan results at a 1:1 ratio. The primary endpoint is measuring change in back pain using a 100mm VAS Back scale at 12 months compared to baseline. Nociscan is positioned as the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful lumbar spine discs. [ "Trial expansion to prestigious Keck Medical Center of USC strengthens study credibility", "Study targets a large market with 266 million people worldwide suffering from degenerative spine disease", "First-of-its-kind noninvasive technology for identifying painful discs", "Partnership with multiple high-profile medical institutions" ]

#ACON #ACONW Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

10 months ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site Aclarion (NASDAQ: ACON) has announced the addition of Texas Back Institute (TBI) as a new site for its CLARITY clinical trial. The trial aims to demonstrate the effectiveness of Nociscan, Aclarion's technology that uses MR Spectroscopy and AI to identify sources of chronic low back pain. The CLARITY study will enroll 300 patients across multiple US sites, including Johns Hopkins Medicine, Northwestern Medicine, and Advocate Aurora Research Institute.The randomized trial will evaluate patients scheduled for 1- or 2-level discogenic low back pain surgery, with surgeons either blinded or unblinded to Nociscan results. The primary endpoint is measuring change in back pain after 12 months. Nociscan is positioned as the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful lumbar spine discs, targeting a global market of approximately 266 million people suffering from degenerative spine disease and low back pain.

#ACON #ACONW Aclarion Announces Texas Back Institute as New CLARITY Trial Site

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

10 months ago

Aclarion Welcomes Advocate Health as CLARITY Trial Site Aclarion (NASDAQ: ACON) announced that Advocate Aurora Research Institute, part of Advocate Health, has joined as a site for their CLARITY trial. The trial aims to demonstrate the clinical and economic value of Nociscan, Aclarion's diagnostic platform that uses biomarkers and AI to identify sources of chronic low back pain.The CLARITY trial is a prospective, randomized study that will enroll 300 patients across multiple US sites, evaluating surgical treatment of 1- or 2-level discogenic low back pain. The study will compare outcomes between surgeons who are blinded and unblinded to Nociscan results, with the primary endpoint measuring change in back pain at 12 months. Dr. Nicholas Theodore of Johns Hopkins Medicine serves as the principal investigator.

#ACON #ACONW Aclarion Welcomes Advocate Health as CLARITY Trial Site

www.stocktitan.net/news/ACON/aclarion-welco...

StockTitan

@stocktitan.net

11 months ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana Aclarion,

#ACON #ACONW Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

11 months ago

New Research: AI-Powered Spine Technology Cuts Patient Costs by $1,712, Boosts Surgery Success 10% Peer-reviewed study reveals Nociscan's superior cost-effectiveness vs traditional spine diagnostics. See how AI biomarkers improve surgical outcomes. Get insights.

#ACON #ACONW Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

1 year ago

Revolutionary AI-Powered Back Pain Diagnostic Tool Gains Ground in Los Angeles Healthcare Market Aclarion's AI-driven Nociscan platform for chronic back pain diagnosis extends to Santa Monica's premier imaging center. See how this expansion impacts healthcare delivery.

#ACON #ACONW Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

1 year ago

AI Healthcare Pioneer Aclarion Raises $20M, Backs Revolutionary Back Pain Technology AI-powered Nociscan platform shows 97% success rate in chronic back pain treatment. Company expands globally with $15M cash reserves and zero debt. See growth strategy.

#ACON #ACONW Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

www.stocktitan.net/news/ACON/aclarion-provi...

StockTitan

@stocktitan.net

1 year ago

Major Launch: Ex-AIG Chief Leads New A-Rated Reinsurer Backed by $B Investors New reinsurance platform Mereo secures A- rating and heavyweight backing. Led by former AIG CEO, targeting property and specialty markets. Full analysis inside.

#ACON #ACONW Aclarion Announces Reverse Stock Split

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

1 year ago

Aclarion Sets Major Corporate Update: 8-K Filed, 10-K Coming for AI Healthcare Pioneer Healthcare AI innovator Aclarion submits 8-K filing and schedules comprehensive 10-K report, promising key updates on its chronic back pain diagnostic technology platform.

#ACON #ACONW Aclarion Provides Shareholder Update

www.stocktitan.net/news/ACON/aclarion-provi...

StockTitan

@stocktitan.net

1 year ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey Aclarion (NASDAQ: ACON) has announced expansion plans for its Nociscan technology across multiple sites in New York and New Jersey through RadNet affiliates. Lenox Hill Radiology (LHR), operating 79 locations in New York, and New Jersey Imaging Network (NJIN), with 33 locations, will increase Nociscan accessibility in response to growing market demand.The expansion builds on existing Nociscan sites and is facilitated by increased MR Spectroscopy (MRS) availability and enhanced remote operations capabilities within RadNet. LHR Park Avenue serves leading spine physicians from private practices and organizations like Weill Cornell, while NJIN-Union supports both local and out-of-market referrals through convenient airport access.Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively identify painful discs in the lumbar spine, demonstrating a 97% surgical success rate when all pain-positive discs identified by Nociscan are treated.

#ACON #ACONW Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

1 year ago

How Aclarion's New Scripps Health Deal Could Transform Chronic Back Pain Diagnosis Aclarion's Nociscan technology for chronic low back pain diagnosis enters Southern California's largest healthcare system serving 3.2M patients.

#ACON #ACONW Aclarion Announces First Commercial Agreement with Scripps Health

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

1 year ago

Aclarion Postpones Critical Stockholder Vote - Will March 5 Meeting Secure Enough Support? Aclarion adjourns Special Meeting to gather additional votes for key proposals. Previously submitted proxies remain valid unless revoked before March 4.

#ACON #ACONW Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders

www.stocktitan.net/news/ACON/aclarion-inc-a...

StockTitan

@stocktitan.net

1 year ago

Major Clinical Breakthrough: Leading Medical Center Tests Revolutionary AI-Powered Spine Surgery Technology Northwestern Medicine leads groundbreaking study of Nociscan's AI-powered spine diagnosis platform. 300-patient trial aims to transform surgical outcomes for chronic back pain patients.

#ACON #ACONW Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

1 year ago

#ACON #ACONW Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

www.stocktitan.net/news/ACON/aclarion-annou...

StockTitan

@stocktitan.net

1 year ago

#ACON #ACONW Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

www.stocktitan.net/news/ACON/aclarion-to-pr...